Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03056755 |
Title | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Novartis Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | CAN |